Semaglutide Review Dodges the Real Off-Label Questions
Narrative review skims efficacy data but ignores practical realities of semaglutide use in healthy adults seeking weight loss.
Published April 21, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This narrative review synthesizes existing data on semaglutide for weight loss in non-diabetic adults, covering efficacy, safety profiles, and practical implementation considerations. The authors compiled evidence from clinical trials and real-world studies to assess outcomes in populations without diabetes.
Why It Matters
Semaglutide, a GLP-1 receptor agonist, works through multiple mechanisms: delayed gastric emptying, enhanced satiety signaling, and direct hypothalamic appetite suppression. The STEP trials showed 15-17% weight loss in non-diabetic adults at 2.4mg weekly doses — impressive numbers that drove massive off-label prescribing.
But here's what matters more: the practical questions this review should address but likely glosses over. What happens when you stop? The rebound weight gain data is brutal — most patients regain 60-70% of lost weight within a year of discontinuation. What about the psychological dependency that develops when appetite control becomes externally mediated? These aren't just "side effects" — they're fundamental pharmacological realities.
The safety profile in healthy adults differs meaningfully from diabetic populations. Non-diabetics face higher rates of gastroparesis, particularly at higher doses. The pancreatitis risk, while low, becomes more concerning when you're treating cosmetic weight loss rather than metabolic disease.
What I'd Watch For
Narrative reviews are inherently selective — authors choose which studies to emphasize. I'd want to see honest discussion of discontinuation rates (often 30-40% in real-world use) and long-term metabolic effects. Does chronic GLP-1 agonism alter endogenous incretin production? The preclinical data suggests potential downregulation, but human studies are sparse.
The "practical considerations" angle should cover cost-benefit analysis, but most reviews avoid the elephant in the room: $1,200+ monthly for cosmetic weight loss in healthy adults. That's not a medical decision — it's a lifestyle choice with medical consequences.
Bottom Line
Semaglutide works for weight loss, but narrative reviews rarely capture the nuanced risk-benefit calculation for off-label use in healthy adults. The efficacy data is solid, but the practical realities — financial, psychological, and physiological dependence — deserve more honest assessment than most reviews provide.